ReviewPatient preference and adherence2017
Peripherally acting μ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy.
Review in Patient preference and adherence, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- The Influence of Age on Central Effects of Methylnaltrexone in Patients with Opioid-Induced Constipation.Drugs & aging · 2021Trial
- Effects of naloxegol on whole gut transit in opioid-naïve healthy subjects receiving codeine: A randomized, controlled trial.Neurogastroenterology and motility · 2018Trial
- Ruminococcus bromii alleviates constipation by pullulanase-driven resistant starch degradation and microbiota modulation.NPJ biofilms and microbiomes · 2025Article
- Beetroot leaf extract enhances gut motility in a model of loperamide-induced constipation in male rats: A phytopharmacological study.Physiological reports · 2025Article
- Opioid-Induced Constipation in Patients with Cancer Pain in Japan (OIC-J Study): A Post Hoc Analysis.Journal of clinical medicine · 2021Article
- Opioid therapy duration before naldemedine treatment is a significant independent risk of diarrhea: a retrospective cohort study.Journal of pharmaceutical health care and sciences · 2021Article
- Blood-brain barrier: mechanisms governing permeability and interaction with peripherally acting μ-opioid receptor antagonists.Regional anesthesia and pain medicine · 2020Article
- Synthesis, Radiosynthesis and Biological Evaluation of Buprenorphine-Derived Phenylazocarboxamides as Novel μ-Opioid Receptor Ligands.ChemMedChem · 2020Article
- Comparisons of In Vivo and In Vitro Opioid Effects of Newly Synthesized 14-Methoxycodeine-6-Molecules (Basel, Switzerland) · 2020Article
- Opioid-induced bowel dysfunction: suggestions from a multidisciplinary expert Board.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019Article
- Incidence of opioid-induced constipation in Japanese patients with cancer pain: A prospective observational cohort study.Cancer medicine · 2019Observational
- Design, synthesis and evaluation ofNuclear medicine and biology · 2019Article
- Safety of oral methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain.Journal of pain research · 2019Article
- Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label Phase III studies.Journal of pain research · 2019Article
- Peripherally Acting μ-Opioid Receptor Antagonists for the Treatment of Opioid-Related Side Effects: Mechanism of Action and Clinical Implications.Journal of pharmacy practice · 2018Review
- Oral methylnaltrexone is efficacious and well tolerated for the treatment of opioid-induced constipation in patients with chronic noncancer pain receiving concomitant methadone.Journal of pain research · 2018Article
- Oral methylnaltrexone does not negatively impact analgesia in patients with opioid-induced constipation and chronic noncancer pain.Journal of pain research · 2018Article
- Methylnaltrexone: Peripherally Acting µ-Opioid Receptor Antagonist.Journal of the advanced practitioner in oncologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Opioid-induced constipation (OIC), a prevalent and distressing side effect of opioid therapy, does not reliably respond to treatment with conventional laxatives. OIC can be a treatment-limiting adverse event. Recent advances in medications with peripherally acting μ-opioid receptor antagonists, such as methylnaltrexone, naloxegol, and alvimopan, hold promise for treating OIC and thus extending the benefits of opioid analgesia to more chronic pain patients. Peripherally acting μ-opioid receptor antagonists have been clinically tested to improve bowel symptoms without compromise to pain relief, although there are associated side effects, including abdominal pain. Other treatment options include fixed-dose combination products of oxycodone analgesic together with naloxone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.